A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
Lia Gore(Children's Hospital Colorado), Bodour Salhia(University of Southern California), Winnie S. Liang(Translational Genomics Research Institute), Todd M. Cooper(Seattle Children's Hospital), Frank Alvaro(ANZCHOG), Soheil Meshinchi(Fred Hutch Cancer Center), Gerald Gooden(University of Southern California), Jason E. Farrar(Arkansas Children's Hospital), Laura Martin(Nationwide Children's Hospital), Margaret E. Macy(Children's Hospital Colorado), Jessica A. Pollard(Maine Medical Center), Aru Narendran(University of Calgary), John D. Carpten(City of Hope), Daniel Wai(Institute of Molecular Medicine), Jessica Boklan(University of Arizona), Christophe Legendre(Translational Genomics Research Institute), Carola Arndt(Mayo Clinic), David Lee(Johns Hopkins University), Philip Barnette(Primary Children's Hospital), R.J. Arceci(Johns Hopkins University), Timothy J. Triche(RF Laboratories (United States))
Cited by 45
Related Papers
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
|New England Journal of Medicine|1999|1.2k
Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
|New England Journal of Medicine|2002|986
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724